Exploring the possible targeting strategies of liposomes against methicillin-resistant Staphylococcus aureus (MRSA)

Rani, Nur Najihah Izzati Mat; Hussein, Zahraa Mustafa; Mustapa, Fahimi; Azhari, H. Nour; Sekar, Mahendran; Chen, Xiang Yi; Amin, Mohd Cairul Iqbal Mohd

doi:10.1016/j.ejpb.2021.04.021

Cited by 11 publications

(5 citation statements)

References 219 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, liposomes have shown effectiveness in antibiotic delivery and bacterial growth inhibition for a number of decades, − owing to their ability to increase the local concentration of antibiotics within bacterial cells, − with improved pharmacokinetics and biodistribution. Indeed, antibiotics delivered by liposomes have exhibited efficacy against antibiotic-resistant microorganisms; , for example, liposomal delivery has been shown to increase the amount of intracellular methicillin accumulation and reduce bacterial populations by 96%, as compared to 40% for free methicillin . Likewise, liposomal delivery also has been shown to reduce the MIC of vancomycin against MRSA to two- to four-fold lower than that of free vancomycin. , Moreover, vancomycin-loaded liposomes have been shown to significantly reduce MRSA populations in a mouse surgical wound model relative to that of free vancomycin at the end of the 9th and 14th days of treatment …”

Section: Introductionmentioning

confidence: 99%

Controlled Delivery of Vancomycin from Collagen-tethered Peptide Vehicles for the Treatment of Wound Infections

et al. 2023

View full text Add to dashboard Cite

Despite the great promise of antibiotic therapy in wound infections, antibiotic resistance stemming from frequent dosing diminishes drug efficacy and contributes to recurrent infection. To identify improvements in antibiotic therapies, new antibiotic delivery systems that maximize pharmacological activity and minimize side effects are needed. In this study, we developed elastin-like peptide and collagen-like peptide nanovesicles (ECnVs) tethered to collagencontaining matrices to control vancomycin delivery and provide extended antibacterial effects against methicillin-resistant Staphylococcus aureus (MRSA). We observed that ECnVs showed enhanced entrapment efficacy of vancomycin by 3-fold as compared to liposome formulations. Additionally, ECnVs enabled the controlled release of vancomycin at a constant rate with zero-order kinetics, whereas liposomes exhibited first-order release kinetics. Moreover, ECnVs could be retained on both collagen-fibrin (co-gel) matrices and collagen-only matrices, with differential retention on the two biomaterials resulting in different local concentrations of released vancomycin. Overall, the biphasic release profiles of vancomycin from ECnVs/co-gel and ECnVs/ collagen more effectively inhibited the growth of MRSA for 18 and 24 h, respectively, even after repeated bacterial inoculation, as compared to matrices containing free vancomycin, which just delayed the growth of MRSA. Thus, this newly developed antibiotic delivery system exhibited distinct advantages for controlled vancomycin delivery and prolonged antibacterial activity relevant to the treatment of wound infections.

show abstract

Section: Introductionmentioning

confidence: 99%

Controlled Delivery of Vancomycin from Collagen-tethered Peptide Vehicles for the Treatment of Wound Infections

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Baicalin suppressed the production of pro-inflammatory cytokines, nitric oxide (NO), nuclear factor-B (NF-B), caspase-3 activity, and reversed organ harm brought on by endotoxic shock in vivo while decreasing LPS-stimulated macrophage activation in vitro (Shahcheraghi et al, 2023). Additionally, baicalin can be used as an adjuvant therapy for both ex vivo methicillin-resistant Staphylococcus aureus (MRSA) and animal meningitis caused by Escherichia coli (E. coli) (Divyakolu et al, 2019;dos Santos Ramos et al, 2020;Rani et al, 2021).…”

Section: Baicalinmentioning

confidence: 99%

Role of Flavonoids in Sepsis: Advances and Future Prospects

Esmail,

Sahlan

2024

Preprint

View full text Add to dashboard Cite

Due to the host immunological disease brought on by infection is sepsis, multiple organ dysfunction syndrome (MODS), which has a high morbidity and mortality rate, could be the result. With advances in pathogen detection technologies, breakthroughs in anti-infection drugs, and the creation of organ function support, the clinical diagnosis and treatment of sepsis have advanced significantly. Pathogen-induced abnormal immunological responses, which can range from excessive inflammation to immunosuppression, are recognized to play a significant role in the high death rate. Unfortunately, no medications that are specifically intended to treat sepsis have been licensed. In order to offer a theoretical foundation for the management of sepsis, we will now discuss current advancements in research on immunological responses in sepsis. The prognosis of sepsis patients may be improved by developing and optimizing a dynamic immune system treatment plan based on anti-infection therapy, fluid replacement, support for organ function, and timely application of immunomodulatory therapies

show abstract

“…Methicillin-resistant Staphylococcus aureus (MRSA) has garnered considerable interest as a major drug-resistant pathogen for causing soft tissue infections, pneumonia, bacteremia, and other deadly illnesses. Unfortunately, the therapeutic efficacy of vancomycin (Van), the well-known final line of defense against MRSA infections, is diminishing year after year (Rani et al, 2021). Chen et al reported that biomimetic recycled RBC@Fe 3 O 4 nanoparticles are antibacterial agents.…”

Section: Red Blood Cell Membrane-coated Nanoparticlesmentioning

confidence: 99%

Recent advances of cell membrane-coated nanoparticles for therapy of bacterial infection

Song

Zheng

et al. 2023

Front. Microbiol.

View full text Add to dashboard Cite

The rapid evolution of antibiotic resistance and the complicated bacterial infection microenvironments are serious obstacles to traditional antibiotic therapy. Developing novel antibacterial agents or strategy to prevent the occurrence of antibiotic resistance and enhance antibacterial efficiency is of the utmost importance. Cell membrane-coated nanoparticles (CM-NPs) combine the characteristics of the naturally occurring membranes with those of the synthetic core materials. CM-NPs have shown considerable promise in neutralizing toxins, evading clearance by the immune system, targeting specific bacteria, delivering antibiotics, achieving responsive antibiotic released to the microenvironments, and eradicating biofilms. Additionally, CM-NPs can be utilized in conjunction with photodynamic, sonodynamic, and photothermal therapies. In this review, the process for preparing CM-NPs is briefly described. We focus on the functions and the recent advances in applications of several types of CM-NPs in bacterial infection, including CM-NPs derived from red blood cells, white blood cells, platelet, bacteria. CM-NPs derived from other cells, such as dendritic cells, genetically engineered cells, gastric epithelial cells and plant-derived extracellular vesicles are introduced as well. Finally, we place a novel perspective on CM-NPs’ applications in bacterial infection, and list the challenges encountered in this field from the preparation and application standpoint. We believe that advances in this technology will reduce threats posed by bacteria resistance and save lives from infectious diseases in the future.

show abstract

Exploring the possible targeting strategies of liposomes against methicillin-resistant Staphylococcus aureus (MRSA)

Cited by 11 publications

References 219 publications

Controlled Delivery of Vancomycin from Collagen-tethered Peptide Vehicles for the Treatment of Wound Infections

Controlled Delivery of Vancomycin from Collagen-tethered Peptide Vehicles for the Treatment of Wound Infections

Role of Flavonoids in Sepsis: Advances and Future Prospects

Recent advances of cell membrane-coated nanoparticles for therapy of bacterial infection

Contact Info

Product

Resources

About